Related Experiment Video

Updated: Aug 29, 2026

Hippocampal Insulin Microinjection and In vivo Microdialysis During Spatial Memory Testing
10:32

Hippocampal Insulin Microinjection and In vivo Microdialysis During Spatial Memory Testing

Published on: January 11, 2013

Treatment of extreme hyperglycemia monitored with intracerebral microdialysis

Fredrik Ahlsson1, Rolf Gedeborg, Göran Hesselager

  • 1Department of Pediatrics, Uppsala University Hospital, Uppsala, Sweden.

Pediatric Critical Care Medicine : a Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies
|December 31, 2003
PubMed

Insights

Intracerebral microdialysis monitored a pediatric patient with hyperosmolar hyperglycemic nonketotic syndrome. Rapid blood glucose reduction increased the brain/subcutaneous glucose ratio, a potential risk for brain edema.

Area of Science:

  • Pediatric Endocrinology
  • Neurocritical Care
  • Metabolic Disorders

Background:

  • Hyperosmolar hyperglycemic nonketotic syndrome (HHNS) is a severe complication of diabetes.
  • Management of extreme hyperglycemia in children requires careful monitoring to prevent complications like cerebral edema.

Observation:

  • A case report details an 11-year-old boy with new-onset diabetes presenting with severe hyperglycemia (100 mmol/L) and high serum osmolality (448 mOsm/kg).
  • Intracerebral and subcutaneous microdialysis were used alongside intracranial pressure monitoring during treatment to correct the hyperosmolar state.

Findings:

  • Subcutaneous dialysate glucose correlated with blood glucose levels.
  • The brain-to-subcutaneous glucose ratio varied (mean 0.43), increasing sharply when blood glucose decreased rapidly, indicating slower brain glucose normalization.
  • Rapid blood glucose reduction was associated with a higher brain/subcutaneous glucose ratio.

Implications:

  • Intracerebral microdialysis is a viable tool for monitoring brain glucose levels during HHNS treatment.
  • A rapid decrease in blood glucose may increase the risk of osmotic brain edema.
  • This monitoring technique can aid in optimizing treatment strategies for pediatric patients with extreme hyperglycemia.
Abstract

More Related Videos

Hyperglycemic Clamp and Hypoglycemic Clamp in Conscious Mice07:35

Hyperglycemic Clamp and Hypoglycemic Clamp in Conscious Mice

Published on: January 26, 2024

Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats08:47

Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats

Published on: November 8, 2018

Related Concept Videos

Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
Hypoglycemia01:26

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
Diabetic Ketoacidosis l: Introduction01:25

Diabetic Ketoacidosis l: Introduction

DefinitionDiabetic ketoacidosis (DKA) is an acute, life-threatening complication of diabetes mellitus, characterized by a triad of hyperglycemia (blood glucose >250 mg/dL), ketonemia or ketonuria, and metabolic acidosis (arterial pH <7.30 and serum bicarbonate <18 mEq/L). It results from insulin deficiency combined with elevated levels of counterregulatory hormones—glucagon, catecholamines, cortisol, and growth hormone—leading to increased lipolysis, hepatic ketone production, and...
Diabetic Ketoacidosis ll: Pathophysiology01:22

Diabetic Ketoacidosis ll: Pathophysiology

Diabetic ketoacidosis (DKA) is a metabolic emergency characterized by hyperglycemia, ketonemia, and metabolic acidosis. It results from severe insulin deficiency and an excess of counterregulatory hormones, leading to uncontrolled lipolysis, ketogenesis, and widespread electrolyte and fluid disturbances.Pathophysiology The central event in DKA is a profound loss of insulin action. Without insulin, glucose uptake in insulin-dependent tissues is impaired, while hepatic glucose production...
Type I Diabetes III: Clinical Manifestations01:19

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...